211 related articles for article (PubMed ID: 36656435)
1. Efficacy and safety of oral gonadotropin-releasing hormone antagonists in moderate-to-severe endometriosis-associated pain: a systematic review and network meta-analysis.
Xin L; Ma Y; Ye M; Chen L; Liu F; Hou Q
Arch Gynecol Obstet; 2023 Oct; 308(4):1047-1056. PubMed ID: 36656435
[TBL] [Abstract][Full Text] [Related]
2. Oral gonadotropin-releasing hormone antagonists for treating endometriosis-associated pain: a systematic review and network meta-analysis.
Yan H; Shi J; Li X; Dai Y; Wu Y; Zhang J; Gu Z; Zhang C; Leng J
Fertil Steril; 2022 Dec; 118(6):1102-1116. PubMed ID: 36283862
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
Taylor HS; Giudice LC; Lessey BA; Abrao MS; Kotarski J; Archer DF; Diamond MP; Surrey E; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Rowan JP; Duan WR; Ng J; Schwefel B; Thomas JW; Jain RI; Chwalisz K
N Engl J Med; 2017 Jul; 377(1):28-40. PubMed ID: 28525302
[TBL] [Abstract][Full Text] [Related]
4. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis.
Surrey ES; Soliman AM; Agarwal SK; Snabes MC; Diamond MP
Fertil Steril; 2019 Aug; 112(2):298-304.e3. PubMed ID: 30992150
[TBL] [Abstract][Full Text] [Related]
5. Medical therapy options for endometriosis related pain, which is better? A systematic review and network meta-analysis of randomized controlled trials.
Samy A; Taher A; Sileem SA; Abdelhakim AM; Fathi M; Haggag H; Ashour K; Ahmed SA; Shareef MA; AlAmodi AA; Keshta NHA; Shatat HBAE; Salah DM; Ali AS; El Kattan EAM; Elsherbini M
J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101798. PubMed ID: 32479894
[TBL] [Abstract][Full Text] [Related]
6. Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results.
Osuga Y; Seki Y; Tanimoto M; Kusumoto T; Kudou K; Terakawa N
BMC Womens Health; 2021 Jun; 21(1):250. PubMed ID: 34154590
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies.
Surrey E; Taylor HS; Giudice L; Lessey BA; Abrao MS; Archer DF; Diamond MP; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Singh SS; Rechberger T; Agarwal SK; Duan WR; Schwefel B; Thomas JW; Peloso PM; Ng J; Soliman AM; Chwalisz K
Obstet Gynecol; 2018 Jul; 132(1):147-160. PubMed ID: 29889764
[TBL] [Abstract][Full Text] [Related]
8. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.
Osuga Y; Seki Y; Tanimoto M; Kusumoto T; Kudou K; Terakawa N
Fertil Steril; 2021 Feb; 115(2):397-405. PubMed ID: 32912633
[TBL] [Abstract][Full Text] [Related]
9. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density.
Carr B; Dmowski WP; O'Brien C; Jiang P; Burke J; Jimenez R; Garner E; Chwalisz K
Reprod Sci; 2014 Nov; 21(11):1341-51. PubMed ID: 25249568
[TBL] [Abstract][Full Text] [Related]
10. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial.
Donnez J; Taylor HS; Taylor RN; Akin MD; Tatarchuk TF; Wilk K; Gotteland JP; Lecomte V; Bestel E
Fertil Steril; 2020 Jul; 114(1):44-55. PubMed ID: 32505383
[TBL] [Abstract][Full Text] [Related]
11. Elagolix for endometriosis: all that glitters is not gold.
Vercellini P; Viganò P; Barbara G; Buggio L; Somigliana E;
Hum Reprod; 2019 Feb; 34(2):193-199. PubMed ID: 30551159
[TBL] [Abstract][Full Text] [Related]
12. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
Giudice LC; As-Sanie S; Arjona Ferreira JC; Becker CM; Abrao MS; Lessey BA; Brown E; Dynowski K; Wilk K; Li Y; Mathur V; Warsi QA; Wagman RB; Johnson NP
Lancet; 2022 Jun; 399(10343):2267-2279. PubMed ID: 35717987
[TBL] [Abstract][Full Text] [Related]
13. Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials.
Pokrzywinski RM; Soliman AM; Chen J; Snabes MC; Coyne KS; Surrey ES; Taylor HS
Am J Obstet Gynecol; 2020 Jun; 222(6):592.e1-592.e10. PubMed ID: 31759891
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study.
D'Hooghe T; Fukaya T; Osuga Y; Besuyen R; López B; Holtkamp GM; Miyazaki K; Skillern L
Hum Reprod; 2019 May; 34(5):813-823. PubMed ID: 31067329
[TBL] [Abstract][Full Text] [Related]
15. Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients.
Abrao MS; Surrey E; Gordon K; Snabes MC; Wang H; Ijacu H; Taylor HS
BMC Womens Health; 2021 Jun; 21(1):246. PubMed ID: 34134684
[TBL] [Abstract][Full Text] [Related]
16. Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study.
Carr B; Giudice L; Dmowski WP; O'Brien C; Jiang P; Burke J; Jimenez R; Hass S; Fuldeore M; Chwalisz K
J Endometr Pelvic Pain Disord; 2013 Jul; 5(3):105-115. PubMed ID: 30320043
[TBL] [Abstract][Full Text] [Related]
17. Oral GnRH Antagonists in Combination with Estradiol and Norethindrone Acetate for Pain Relief Associated with Endometriosis: A Review of Evidence of a Novel Class of Hormonal Agents.
Othman ER; Al-Hendy A; Mostafa R; Lambalk CB; Mijatovic V
Int J Womens Health; 2024; 16():309-321. PubMed ID: 38435758
[TBL] [Abstract][Full Text] [Related]
18. Oral Gonadotropin-Releasing Hormone Antagonists in the Treatment of Uterine Myomas: A Systematic Review and Network Meta-analysis of Efficacy Parameters and Adverse Effects.
Telek SB; Gurbuz Z; Kalafat E; Ata B
J Minim Invasive Gynecol; 2022 May; 29(5):613-625. PubMed ID: 34942350
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain.
Taylor HS; Dun EC; Chwalisz K
Pain Manag; 2019 Sep; 9(5):497-515. PubMed ID: 31434540
[TBL] [Abstract][Full Text] [Related]
20. Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain.
Blair HA
Drugs; 2024 Apr; 84(4):449-457. PubMed ID: 38592603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
